New Investors

Showing 4189 articles
Business

Galenica's Five-Year Surge: A 90% Return for Patient Investors

Swiss healthcare group Galenica has delivered robust returns for long-term shareholders, with a total return of 90% over five years, significantly outpacing the broader market. While recent performance has moderated, the stock's journey highlights the value of consistent earnings growth and dividends.

Business

Commerzbank's Meteoric Rise: Is There Still Value Left for Investors?

Following a staggering 92.9% one-year surge, Commerzbank shares have cooled slightly. With the stock now trading around €34.69, analysts are divided: deep-value models signal significant upside, while traditional metrics suggest a fair price. We examine the data and the debate shaping one of Germany's banking turnaround stories.